Physician profile
Carson Daniel Rodeffer
NPI 1679923387
$527.86
in general payments reported to CMS, 2019-2025
16 companies · $85.67 in 2025
The $85.67 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $128 · 2022: $47.75 · 2023: $141 · 2025: $85.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $227.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $124.98 | 2019 | |
| Intuitive Surgical, INC. | $113.19 | 2023 | |
| Organon LLC | $30.59 | 2021-2025 | Nexplanon |
| Pfizer INC. | $28.19 | 2023 | |
| Medtronic, INC. | $26.78 | 2021 | |
| Integra Lifesciences Corporation | $24.33 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.42 | 2022 | |
| Abbvie INC. | $21.56 | 2021 | |
| Meditrina | $21.32 | 2025 | |
| Hologic Sales and Service, LLC | $19.15 | 2021 | |
| Myovant Sciences INC. | $18.77 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.93 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $15.93 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $15.66 | 2021 | |
| Boston Scientific Corporation | $14.27 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Femselect INC. | $13.79 | 2025 | Enplace |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carson Rodeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.